Why is Cohance Life falling/rising?

As of 13-Nov, Cohance Lifesciences Ltd is experiencing a significant decline in its stock price, currently at Rs. 629.50, which reflects a decrease of Rs. 60.05 or 8.71%. The stock has hit a new 52-week low of Rs. 621.35 today and has been on a downward trend, losing value for the past 11 consecutive days, resulting in a total drop of 26.33% during this period. The stock's performance over the past week and month shows a decline of 13.02% and 28.88%, respectively, while it has underperformed the sector by 8.92% today. Additionally, the stock is trading below all key moving averages, indicating a bearish trend. The company has a high management efficiency with a return on equity (ROE) of 24.14% and a low debt-to-equity ratio, but these positives are overshadowed by poor long-term growth prospects, as evidenced by an operating profit growth rate of only 2.95% over the last five years and a significant drop in profit after tax (PAT) of 41.1% in the latest quarter. In the broader market context, the stock's performance contrasts sharply with the benchmark Sensex, which has gained 1.40% over the past week and 2.61% over the past month. This stark difference highlights the stock's underperformance, particularly as it has generated a return of -50.00% over the past year compared to the Sensex's 8.74% gain. The presence of 100% of promoter shares being pledged adds further downward pressure in a falling market, contributing to the stock's decline. Overall, the combination of high volatility, falling investor participation, and poor financial results has led to a significant drop in Cohance Lifesciences Ltd's stock price.